Azelastine hydrochloride is under clinical development by CEBINA and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Azelastine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Azelastine hydrochloride overview
Azelastine hydrochloride is under development for the prevention of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or post-exposure anti-COVID-19. It is a repurposed version of azelastine hydrochloride. It is administered through nasal route as a spray.
CEBINA overview
CEBINA is a biotechnology company that offers research and development services. The company provides technology evaluation, discovery and translational research, preclinical development expertise, product development strategy, and clinical feasibility. The company offers various corporate services including strategic business development, licensing, market research, communications, legal and financial support administration, and management services. CEBINA Pipeline includes nasal sprays and vaccines for COVID-19. The CEBINA also provides office and laboratory space BSL2 (Bio Safety Level 2) laboratories with meeting rooms and conference facilities. It serves life science and biotech companies. CEBINA is headquartered in Vienna, Austria.
For a complete picture of Azelastine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
